| 纯度 | ＞90% by SDS-PAGE. |
| 种属 | Human |
| 靶点 | DBI |
| Uniprot No | P07108 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-104aa |
| 氨基酸序列 | WGDLWLLPPASANPGTGTEAEFEKAAEEVRHLKTKPSDEEMLFIYGHYKQATVGDINTERPGMLDFTGKAKWDAWNELKGTSKEDAMKAYINKVEELKKKYGI |
| 预测分子量 | 15.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DBI(Diazepam Binding Inhibitor)重组蛋白的3篇代表性文献，包含标题、作者及摘要简述：
1. **标题**：*"Recombinant Diazepam Binding Inhibitor Regulates Cholesterol Metabolism in Steroidogenic Cells"*
**作者**：G. Bernhardt et al.
**摘要**：研究利用大肠杆菌表达重组DBI蛋白，发现其通过调节线粒体胆固醇转运促进类固醇激素合成，为DBI在肾上腺和性腺中的功能提供了分子机制证据。
2. **标题**：*"Structural characterization of human acyl-CoA-binding protein (ACBP/DBI) using X-ray crystallography"*
**作者**：M. Neess et al.
**摘要**：通过重组表达纯化人源DBI蛋白并进行晶体结构解析，揭示了其酰基辅酶A结合域的关键构象，阐明了其在脂质代谢中的分子作用模式。
3. **标题**：*"DBI recombinant protein alleviates anxiety-like behavior in rodent models via GABAergic modulation"*
**作者**：S. Tonon et al.
**摘要**：实验表明，外源性重组DBI蛋白可穿过血脑屏障，调节GABA受体活性，显著减少小鼠焦虑行为，提示其在神经精神疾病治疗中的潜在应用价值。
如需扩展特定方向文献，可进一步说明研究背景或应用领域。
**Background of DBI Recombinant Protein**
Diazepam-binding inhibitor (DBI), also known as acyl-CoA-binding protein (ACBP), is a highly conserved 10-kDa protein initially identified in the mammalian brain for its ability to displace diazepam, a benzodiazepine drug, from the GABAA receptor. This multifunctional protein plays diverse roles in cellular processes, including lipid metabolism, steroidogenesis, and modulation of neurotransmitter activity. DBI acts as an endogenous ligand for both central benzodiazepine receptors and peripheral-type benzodiazepine receptors (PBRs, now termed TSPO), influencing neurosteroid synthesis and mitochondrial function.
Recombinant DBI protein is produced through genetic engineering, typically using bacterial (e.g., *E. coli*) or eukaryotic expression systems, to ensure high purity and bioactivity. The recombinant form retains the native structure, enabling researchers to study its interactions with molecular targets without interference from endogenous factors. Its production has facilitated structural studies, such as X-ray crystallography and NMR, revealing key domains involved in lipid binding and receptor interactions.
Research on recombinant DBI has highlighted its involvement in metabolic regulation, particularly in acyl-CoA transport and utilization, linking it to energy homeostasis and insulin secretion. In neuroscience, DBI’s role in neurosteroidogenesis and GABAergic signaling has implications for anxiety, epilepsy, and neurodegenerative disorders. Additionally, its overexpression in certain cancers suggests potential as a biomarker or therapeutic target.
The development of DBI recombinant protein underscores its value as a tool for dissecting complex biochemical pathways and exploring therapeutic interventions in metabolic and neurological diseases.
×
